A clinical study of hydroxyethyl starch
Kitamura, Y.; Yamada, A.; Sha, N.; Hamai, R.; Nishimura, K.
Osaka City Medical Journal 18(1): 21-36
1972
ISSN/ISBN: 0030-6096 PMID: 4665972 Document Number: 46962
Document emailed within 1 workday
Related Documents
Jamnicki, M.; Zollinger, A.; Seifert, B.; Popovic, D.; Pasch, T.; Spahn, D.R. 1998: Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography Anesthesia and Analgesia 87(5): 989-993Hayashi, K.; Higashi, H. 1975: Clinical comparison of plasma substitutes, dextran and hydroxyethyl starch Masui. Japanese Journal of Anesthesiology 24(9): 853-859
Weidler, B.; von Bormann, B.; Sommermeyer, K.; Lohmann, E.; Peil, J.; Hempelmann, G. 1991: Pharmacokinetic parameters as criteria for clinical use of hydroxyethyl starch preparations Arzneimittel-Forschung 41(5): 494-498
Kitamura, Y.; Yamada, A.; Sha, N.; Hamanaka, R.; Nishimura, K. 1972: Hespander (hydroxyethyl starch) Masui. Japanese Journal of Anesthesiology 21(11): 1121-1133
Hopf, H.B.; Siepmann, H.P. 1987: Comparative study of the modification of blood, blood coagulation, cardiovascular circulation by 3% modified, fluid gelatins and 6% low-molecular weight hydroxyethyl starch Infusionstherapie und Klinische Ernahrung 14(Suppl 2): 31-35
Meister, D.; Hermann, M.; Mathis, G.A. 1992: Kinetics of hydroxyethyl starch in horses Schweizer Archiv für Tierheilkunde 134(7): 329-339
Fiala, J. 1979: Use of hydroxyethyl starch in blood transfusion and hematology Vnitrni Lekarstvi 25(9): 897-902
Mishler, J.M. 1980: Pharmacokinetics of middle-molecular hydroxyethyl starch (HAS 200/0,5 Infusionstherapie und Klinische Ernahrung 7(2): 96-102
Treib, J.; Haass, A.; Pindur, G. 1997: Coagulation disorders caused by hydroxyethyl starch Thrombosis and Haemostasis 78(3): 974-983
Köhler, H.; Kirch, W.; Vogt, J.; Höffler, D. 1977: Pharmacokinetics of hydroxyethyl starch in kidney failure Verhandlungen der Deutschen Gesellschaft für Innere Medizin 83: 1676-1678
Daszyński, J.; Gryszkiewicz, A.; Kościelak, J. 1976: Erythrocyte freezing in the presence of hydroxyethyl starch Acta Haematologica Polonica 7(2): 155-161
Kościelak, J.; Gryszkiewicz, A.; Schier, J.; Góralski, S. 1977: Fate of C-14 labeled hydroxyethyl starch in mice Acta Haematologica Polonica 8(4): 303-307
Howden, B.O.; Jablonski, P.; Thomas, A.C.; Walls, K.; Biguzas, M.; Scott, D.F.; Grossman, H.; Marshall, V.C. 1990: Liver preservation with UW solution. I. Evidence that hydroxyethyl starch is not essential Transplantation 49(5): 869-872
Ivankovic, S.; Bülow, I. 1975: On the lacking teratogenic effect of the plasmaexpander hydroxyethyl starch in the rat and mouse Der Anaesthesist 24(5): 244-245
Oda, A.; Aoki, A.; Ozaki, T.; Unno, K.; Nagai, N. 1972: Behavior of hydroxyethyl starch in the plasma and urine of man following intravenous infusion Masui. Japanese Journal of Anesthesiology 21(8): 747-753
Vinazzer, H.; Bergmann, H. 1975: The influence of hydroxyethyl starch on postoperative alterations of blood coagulation Der Anaesthesist 24(12): 517-520
Jesch, F.; Hübner, G.; Zumtobel, V.; Zimmermann, M.; Messmer, K. 1979: Hydroxyethyl starch (HAS 450/0.7) in human plasma and liver. Course of concentration and histological changes Infusionstherapie und Klinische Ernahrung 6(2): 112-117
Fioravanti, A.; Cicero, M.R.; Nerucci, F.; Manopulo, R.; Marcolongo, R. 1999: Double-blind controlled clinical study of the efficacy and tolerability of diclofenac-N-(2-hydroxyethyl)-pyrrolidine lecithin gel compared with diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel in patients with peri and extraarticular inflammatory diseases Drugs under Experimental and Clinical Research 25(5): 235-240
Prostakova, T.M.; Glasko, E.N.; Khokhlova, M.P.; Polushina, T.V. 1986: Morphological characteristics of the sequelae from the parenteral administration of solutions of hydroxyethyl starch Arkhiv Patologii 48(7): 43-47
Boldt, J.; von Bormann, B.; Kling, D.; Börner, U.; Mulch, J.; Hempelmann, G. 1986: Volume replacement with a new hydroxyethyl starch preparation (3 percent HES 200/0.5) in heart surgery Infusionstherapie und Klinische Ernahrung 13(3): 145-151